Intranasal Immunization of Ferrets with Commercial Trivalent Influenza Vaccines Formulated in a Nanoemulsion-based Adjuvant

Overview

Journal Clin Vaccine Immunol

Publisher American Society for Microbiology

Specialties Allergy & Immunology
Pathology

Date 2011 May 6

PMID 21543588

Citations 20

Authors

Tarek Hamouda

Joyce A Sutcliffe

Susan Ciotti

James R Baker Jr

Affiliations

Soon will be listed here.

Abstract

NB-1008 is a surfactant-stabilized soybean oil-in-water nanoemulsion (NE) adjuvant with influenza virus antigen incorporated into the NE by simple mixing. Intranasal administration of the antigen with NE adjuvant efficiently produces both mucosal and serum antibody responses as well as a robust cellular Th1 immune response. To demonstrate the adjuvant effect of the W(80)5EC NE, a killed commercial influenza vaccine for intramuscular administration (Fluzone or Fluvirin) was mixed with the W(80)5EC NE adjuvant and administered intranasally to naïve ferrets. After a single intranasal immunization, the adjuvanted influenza vaccine elicited elevated serum hemagglutination inhibition (HAI) geometric mean titers (GMTs) ranging from 196 to 905 for the three hemagglutinin (HA) antigens present in the vaccine, which are approximately 19- to 90-fold higher titers at 1/50 the standard intramuscular commercial nonadjuvanted influenza vaccine dose. Seroconversion rates of 67% to 100% were achieved against each of the three viral strains present. The adjuvanted nasal influenza vaccine also produced significant cross immunity to five other H3N2 influenza virus strains not present in the vaccine and produced sterile immunity after challenge with homologous live virus. No safety issues were observed in 249 ferrets receiving the adjuvanted influenza vaccine. These findings demonstrate the ability of W(80)5EC NE to adjuvant nasally administered influenza vaccine and provide a basis for studying the intranasal W(80)5EC-adjuvanted influenza vaccine in humans.

Citing Articles

Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice.

Ganesan S, Acosta H, Brigolin C, Orange K, Trabbic K, Chen C PLoS One. 2022; 17(11):e0272594.

PMID: 36322572 PMC: 9629544. DOI: 10.1371/journal.pone.0272594.

Development of Nasal Vaccines and the Associated Challenges.

Nian X, Zhang J, Huang S, Duan K, Li X, Yang X Pharmaceutics. 2022; 14(10).

PMID: 36297419 PMC: 9609876. DOI: 10.3390/pharmaceutics14101983.

Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine.

Lin Y, Lin M, Chuang Y, Liu L, Kuo T, Chen C Sci Rep. 2022; 12(1):11369.

PMID: 35790783 PMC: 9255510. DOI: 10.1038/s41598-022-15238-y.

Nanoemulsions: Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks.

Tayeb H, Felimban R, Almaghrabi S, Hasaballah N Colloid Interface Sci Commun. 2021; 45:100533.

PMID: 34692429 PMC: 8526445. DOI: 10.1016/j.colcom.2021.100533.

Nasal Immunization With Small Molecule Mast Cell Activators Enhance Immunity to Co-Administered Subunit Immunogens.

Johnson-Weaver B, Choi H, Yang H, Granek J, Chan C, Abraham S Front Immunol. 2021; 12:730346.

PMID: 34566991 PMC: 8461742. DOI: 10.3389/fimmu.2021.730346.

References

Couch R . Seasonal inactivated influenza virus vaccines. Vaccine. 2008; 26 Suppl 4:D5-9. PMC: 2643340. DOI: 10.1016/j.vaccine.2008.05.076. View

Clements M, Betts R, Tierney E, Murphy B . Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol. 1986; 24(1):157-60. PMC: 268857. DOI: 10.1128/jcm.24.1.157-160.1986. View

Makidon P, Bielinska A, Nigavekar S, Janczak K, Knowlton J, Scott A . Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One. 2008; 3(8):e2954. PMC: 2496893. DOI: 10.1371/journal.pone.0002954. View

Gupta R, RELYVELD E, Lindblad E, Bizzini B, Ben-Efraim S, Gupta C . Adjuvants--a balance between toxicity and adjuvanticity. Vaccine. 1993; 11(3):293-306. DOI: 10.1016/0264-410x(93)90190-9. View

Belshe R, Coelingh K, Ambrose C, Woo J, Wu X . Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine. 2009; 28(9):2149-56. DOI: 10.1016/j.vaccine.2009.11.068. View

Guan Y, Poon L, Cheung C, Ellis T, Lim W, Lipatov A . H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci U S A. 2004; 101(21):8156-61. PMC: 419573. DOI: 10.1073/pnas.0402443101. View

Wood J, Schild G, Newman R, Seagroatt V . An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand. 1977; 5(3):237-47. DOI: 10.1016/s0092-1157(77)80008-5. View

Boyce T, Gruber W, Sannella E, Reed G, Wolff M, Wright P . Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine. 1999; 18(1-2):82-8. DOI: 10.1016/s0264-410x(99)00183-8. View

Belshe R, Gruber W, Mendelman P, Cho I, Reisinger K, Block S . Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000; 136(2):168-75. DOI: 10.1016/s0022-3476(00)70097-7. View

10.

Bielinska A, Janczak K, Landers J, Makidon P, Sower L, Peterson J . Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun. 2007; 75(8):4020-9. PMC: 1952013. DOI: 10.1128/IAI.00070-07. View

11.

Kohn M, Farley T, Sundin D, Tapia R, McFarland L, Arden N . Three summertime outbreaks of influenza type A. J Infect Dis. 1995; 172(1):246-9. DOI: 10.1093/infdis/172.1.246. View

12.

Sweet C, Smith H . Pathogenicity of influenza virus. Microbiol Rev. 1980; 44(2):303-30. PMC: 373180. DOI: 10.1128/mr.44.2.303-330.1980. View

13.

Hamouda T, Chepurnov A, Mank N, Knowlton J, Chepurnova T, Myc A . Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum Vaccin. 2010; 6(7):585-94. DOI: 10.4161/hv.6.7.11818. View

14.

Mossad S . Demystifying FluMist, a new intranasal, live influenza vaccine. Cleve Clin J Med. 2003; 70(9):801-6. DOI: 10.3949/ccjm.70.9.801. View

15.

Schild G, Wood J, Newman R . A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull World Health Organ. 1975; 52(2):223-31. PMC: 2366365. View

16.

De Magistris M . Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev. 2006; 58(1):52-67. DOI: 10.1016/j.addr.2006.01.002. View

17.

CATE T, Couch R, Parker D, Baxter B . Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978. Rev Infect Dis. 1983; 5(4):737-47. DOI: 10.1093/clinids/5.4.737. View

18.

CATE T, Couch R, KASEL J, Six H . Clinical trials of monovalent influenza A/New Jersey/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence. J Infect Dis. 1977; 136 Suppl:S450-5. DOI: 10.1093/infdis/136.supplement_3.s450. View

19.

Myc A, Kukowska-Latallo J, Bielinska A, Cao P, Myc P, Janczak K . Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine. 2003; 21(25-26):3801-14. DOI: 10.1016/s0264-410x(03)00381-5. View

20.

Beyer W, Palache A, de Jong J, Osterhaus A . Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine. 2002; 20(9-10):1340-53. DOI: 10.1016/s0264-410x(01)00471-6. View